Clincial research

NHS England introduce new Innovative Medicines Fund

During an announcement on Wednesday, the NHS chief executive unveiled the introduction of a new Innovative Medicines Fund (IMF) and £680 million of ringfenced funding, made up of £340m existing Cancer Drugs Fund, and £340m IMF funding. It is expected to benefit patients who will receive early access to potentially life-saving new medicines, including cutting-edge gene therapies.

The IMF aims to support patients with any condition, including those with rare and genetic diseases, building on the success of the reformed Cancer Drugs Fund (CDF). It will mean that patients are able to get early access to the most clinically promising treatments, where further data is still needed to support NICE in their final recommendations for the routine use in the NHS.

It is estimated that one in 17 people will be affected by a rare disease in their lifetime. The funding will support the NHS in fast-tracking treatment access for patients. Although this will demonstrate substantial clinical promise, there it still poses significant uncertainty around their clinical and cost effectiveness.

NHS Chief Executive, Simon Stevens, said: “Tens of thousands of patients have already benefitted from the reformed Cancer Drugs Fund, and the new Innovative Medicines Fund will mean all patients – not just those with cancer – will benefit from early access to the most promising and innovative treatments, backed by £680m of ringfenced funds.

“The NHS Long Term Plan is leading to fast track access for innovative, cutting-edge therapies, at the same time as the NHS has also been treating more than 400,000 Covid hospitalised patients, and delivering the fastest and largest vaccination campaign in our history.

“In the last year NHS England has successfully negotiated deals for a range of new treatments, including drugs which may allow toddlers with spinal muscular atrophy the chance to walk thanks to the ‘world’s most expensive drug’, as well as giving cystic fibrosis patients the latest medicines against their debilitating disease.  This new fund will build on these successes, offering hope to even more patients.”

Some of the benefits include improved outcomes for patients and, as part of the NHS Long Term Plan, NHS England’s Commercial Medicines Directorate has used its commercial capabilities to secure access to several innovative medicines for NHS patients, including many ‘world-first’ or ‘first in Europe’ drug deals.

The new funding will be subject to a formal public consultation in the next few weeks, which will also involve patient groups, pharmaceutical companies and other stakeholders.

Health Secretary, Sajid Javid, said: “We want NHS patients to continue to be the first in the world to benefit from cutting-edge treatments as we bust the backlog.

“The Innovative Medicines Fund is another example of the government delivering on its manifesto commitments, and it will significantly reduce the time it takes for the most promising new medicines to reach patients, including children and those with rare diseases, saving lives and giving many people hope for a healthier future.

“This vital new initiative extends the successful Cancer Drugs Fund model to other patients, bringing equal access to the best treatments for all, regardless of the condition.”

The IMF will work in the same way as the CDF, where NICE will have another option rather than an immediate decision about routine availability on the NHS.

In the last five years the CDF has provided more than 64,000 people access to life-extending or potentially life-saving drugs, that might not usually have been available for years.

NHE Sept/Oct 21

NHE Sept/Oct 21

Improving care for long-term conditions

Join us in our September/October edition of National Health Executive, as we explore a range of topics impacting and improving the care that we can deliver to patients, the facilities within which we deliver them, and the opportunities in the digital space to accent and evolve our care capabilities


View all videos
National Health Executive Presents

National Health Executive Presents

NHE365 Virtual Festival: Digital Healthcare

The integration of new technology, such as using virtual outpatient appointments instead of face-to-face reviews of patients in the hospital. Adapting the ways in which our NHS workers serve people has been critical in continuing to provide high-quality treatment, a positive patient experience and preventing Covid-19 transmission during the pandemic. Our healthcare sector has the potential to transform the way we continue to provide essential services while also improving patient care. But how easy is the integration of these innovations into routine NHS practice?

On the 28th of October, at the NHE365 Virtual Hospitals & Technology Enabled Care online event, we will be discussing patient flow and experience, reducing waiting times, reducing the patient backlog and increasing technology adoption. Will you be attending? 

Finger on the Pulse

Ep 14. Health messaging is a science, Professor Craig Jackson

On Episode 14 of NHE's Finger on the Pulse podcast, we're joined by Professor Craig Jackson, Professor of Occupational Health Psychology
Birmingham City University to discuss the coronavirus pandemic, the health messaging around it and how those in power have missed a trick by overlooking the key role of psychology in informing the public of restrictions, measures and the ever-changing situation

More articles...

View all